Coya Therapeutics, Inc. (COYA) Key Metrics
COYA valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $99.7M
- Enterprise value
- $75.5M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 12.4 10-yr median 12.5
- Price / book
- 2.7 10-yr median 2.2
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 0.58
COYA key metrics, 2020–2025
Fiscal year ended December 31, 2025 · U.S. dollarsCOYA valuation Price multiples at each fiscal year-end price.
Price / sales−50.3%
12.2
2025 · hover or tap a bar for each year
20202025
Price / book+2.2%
2.3
2025 · hover or tap a bar for each year
20202025
Free cash flow yield+0.7 pts
−11.1%
2025 · hover or tap a bar for each year
20202025
COYA returns How much profit the business earns on the capital it uses.
Return on equity−11.8 pts
−51.4%
2025 · hover or tap a bar for each year
20202025
Return on assets−10.3 pts
−45.0%
2025 · hover or tap a bar for each year
20202025
Free cash flow margin+154.3 pts
−135.2%
2025 · hover or tap a bar for each year
20202025
Asset turnover+103.0%
0.17
2025 · hover or tap a bar for each year
20202025
COYA per-share figures Results divided by the shares outstanding at year-end.
Revenue per share+103.6%
$0.47
2025 · hover or tap a bar for each year
20202025
Earnings per share
−$1.27
2025 · hover or tap a bar for each year
20202025
Free cash flow per share
−$0.64
2025 · hover or tap a bar for each year
20202025
Book value per share−1.0%
$2.57
2025 · hover or tap a bar for each year
20202025
Shares outstanding+9.8%
16.7M
2025 · hover or tap a bar for each year
20202025
COYA financial health Debt, liquidity and how easily interest is covered.
Net debt−$8.5M
−$46.8M
2025 · hover or tap a bar for each year
20202025
Current ratio−26.6%
8.50
2025 · hover or tap a bar for each year
20202025
COYA efficiency & capital use Working capital cycle and where the cash goes.
Days payables outstanding+17,629 days
17,671 days
2025 · hover or tap a bar for each year
20202025
Capex / revenue0.0 pts
0.0%
2025 · hover or tap a bar for each year
20202025
COYA valuation history
Fiscal year-endToday6-year median
COYA returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
COYA debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
COYA price vs earnings per share
Share price at year-endEPS (right axis)
COYA key metrics
2020–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Valuation | ||||||
| Market capitalization | $97.0M | $87.3M | $75.3M | $47.1M | — | — |
| Enterprise value | $50.2M | $49.0M | $43.4M | $54.2M | — | — |
| Price / sales | 12.2 | 24.6 | 12.5 | — | — | — |
| Price / book | 2.3 | 2.2 | 2.1 | — | — | — |
| EV / sales | 6.3 | 13.8 | 7.2 | — | — | — |
| Earnings yield | −21.9% | −17.0% | −10.6% | −26.0% | — | — |
| Free cash flow yield | −11.1% | −11.8% | −14.9% | −15.4% | — | — |
| Share price at fiscal year-end | $5.80 | $5.73 | $7.41 | $4.74 | — | — |
| Per share | ||||||
| Revenue per share | $0.47 | $0.23 | $0.59 | $0.00 | $0.00 | — |
| Earnings per share | −$1.27 | −$0.98 | −$0.79 | −$1.23 | −$0.74 | — |
| Operating cash flow per share | −$0.64 | −$0.68 | −$1.10 | −$0.73 | −$0.59 | — |
| Free cash flow per share | −$0.64 | −$0.68 | −$1.10 | −$0.73 | −$0.61 | — |
| Cash per share | $2.80 | $2.52 | $3.21 | $0.60 | $0.66 | — |
| Book value per share | $2.57 | $2.60 | $3.51 | −$0.84 | $0.55 | — |
| Tangible book value per share | $2.57 | $2.60 | $3.51 | −$0.84 | $0.55 | — |
| Capex per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.02 | — |
| Debt per share | — | — | $0.07 | $1.30 | — | — |
| Shares outstanding | 16.7M | 15.2M | 10.2M | 9.9M | 6.6M | — |
| Change in shares outstanding | +9.8% | +49.9% | +2.2% | +50.7% | — | — |
| Returns & profitability | ||||||
| Return on equity (ROE) | −51.4% | −39.6% | −58.6% | — | −81.9% | −13.2% |
| Return on invested capital (ROIC) | — | −548.4% | −526.7% | — | — | — |
| Return on assets (ROA) | −45.0% | −34.8% | −32.2% | −185.7% | −72.3% | −12.6% |
| Return on tangible assets | −42.5% | −33.6% | −19.4% | −145.8% | −102.1% | −12.6% |
| Free cash flow margin | −135.2% | −289.5% | −186.4% | — | — | — |
| Financial health | ||||||
| Total debt | — | — | $723,852 | $13.0M | — | — |
| Cash & short-term investments | $46.8M | $38.3M | $32.6M | $5.9M | $4.3M | $8.7M |
| Net debt | −$46.8M | −$38.3M | −$31.9M | $7.0M | −$4.3M | −$8.7M |
| Debt / equity | — | — | 0.02 | — | — | — |
| Debt / assets | — | — | 0.02 | 1.54 | — | — |
| Net debt / EBITDA | — | — | — | — | — | −835.73 |
| Current ratio | 8.50 | 11.59 | 8.15 | 1.88 | 3.99 | 19.57 |
| Quick ratio | 8.50 | 11.59 | 8.15 | 1.88 | 3.99 | 19.57 |
| Interest coverage | — | — | — | -4.0 | -226.7 | -26.7 |
| Working capital | $44.1M | $40.5M | $36.1M | $3.4M | $3.4M | $8.3M |
| Invested capital | −$3.8M | $1.2M | $3.7M | −$1.4M | −$696,451 | −$418,854 |
| Tangible asset value | $43.0M | $39.6M | $35.6M | −$8.4M | $3.6M | $8.3M |
| Net current asset value | $43.0M | $39.5M | $35.6M | −$9.6M | $3.4M | $8.3M |
| Graham net-net per share | $2.38 | $2.24 | $3.21 | −$1.09 | $0.48 | — |
| Capital allocation | ||||||
| Capex / revenue | 0.0% | 0.0% | 0.0% | — | — | — |
| Capex / depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 8.48 | 0.00 |
| Stock-based compensation / revenue | 54.0% | 74.9% | 14.5% | — | — | — |
| R&D / revenue | 210.6% | 334.6% | 100.7% | — | — | — |
| SG&A / revenue | 144.1% | 250.0% | 130.5% | — | — | — |
| Efficiency | ||||||
| Days sales outstanding | — | 422.6 | 456.1 | — | — | — |
| Days payables outstanding | 17,670.7 | 42.2 | 98.6 | 110.5 | 14,758.9 | — |
| Cash conversion cycle (days) | — | 380.4 | 357.5 | — | — | — |
| Receivables turnover | — | 0.86 | 0.80 | — | — | 0.00 |
| Payables turnover | 0.02 | 8.65 | 3.70 | 3.30 | 0.02 | — |
| Asset turnover | 0.17 | 0.08 | 0.24 | 0.00 | 0.00 | 0.00 |
| Average receivables | — | $4.1M | $7.5M | — | — | $1,000 |
| Average payables | $1.3M | $1.4M | $1.5M | $1.3M | $652,344 | $447,121 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from COYA's annual financial statements (latest annual report filed March 16, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
COYA valuation and financial ratios
Coya Therapeutics earned a return on equity of −51.4% in fiscal 2025.
See the COYA income statement, the COYA chart for price history, or the COYA stock overview for the latest quote and news.
COYA key metrics FAQ
What is Coya Therapeutics's return on equity?
Coya Therapeutics's return on equity (ROE) was −51.4% in fiscal 2025: net income of -$21.2 million on average shareholders' equity of $41.3 million.
What is Coya Therapeutics's free cash flow yield?
Coya Therapeutics generated -$10.7 million of free cash flow in fiscal 2025, a free cash flow yield of −11.1% on its market value at year-end ($97.0 million).
What is Coya Therapeutics's current ratio?
Coya Therapeutics's current ratio was 8.50 at the end of fiscal 2025: current assets were 8.50 times current liabilities.